1-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-pyrrolium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 1-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-pyrrolium
• 英文别名: 1-Hydroxy-2,2-dimethyl-3,4-dihydropyrrol-1-ium
• 化学式: C₆H₁₂NO
• 分子量: 114.167
• InChiKey: IVKKELNYLUICGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  23.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5,5-dimethylpyrroline N-oxide 在 氢气 作用下， 以 水 为溶剂， 生成 1-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-pyrrolium 、 1-Hydroperoxy-2,2-dimethyl-3,4-dihydro-2H-pyrrolium
  参考文献：
  名称：

  水溶液声解中的氢原子反应

  摘要：

  DOI：

  10.1021/j100311a026

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION<br/>[FR] COMPOSÉS POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：GILEAD SCIENCES INC

  公开号：WO2018144605A1

  公开（公告）日：2018-08-09

  The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

  本公开涉及一般与化合物和药物组合物有关，这些化合物和药物组合物可用于治疗乙型肝炎病毒感染的方法。
• Compounds for the treatment of hepatitis B virus infection
  申请人：Gilead Sciences, Inc.

  公开号：US10442804B2

  公开（公告）日：2019-10-15

  The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

  本公开一般涉及可用于治疗乙型肝炎病毒感染方法的化合物和药物组合物。
• Protein kinase C inhibitors and uses thereof
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10792282B2

  公开（公告）日：2020-10-06

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本公开涉及的化合物可作为蛋白激酶 C (PKC) 的抑制剂，因此可用于治疗通过 PKC 的活性介导或维持的各种疾病和失调。本公开还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的工艺以及在这些工艺中有用的中间体。
• Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US11066417B2

  公开（公告）日：2021-07-20

  Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

  式 (I) 的化合物： 公开了前述化合物的药学上可接受的盐、前述化合物的氚代衍生物以及前述化合物的代谢物。还公开了包含上述物质的药物组合物、使用上述物质治疗囊性纤维化的方法以及上述物质的制造方法。
• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20190248809A1

  公开（公告）日：2019-08-15

  Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.